BPC-157 + TB-500 Dosage & Protocol: What Is Actually Known

If you are searching for a BPC-157 + TB-500 dosage per day, you have likely already noticed the problem: every source gives a different number, few explain what "TB-500" even refers to, and none point to a human clinical trial. That is not a research gap on your end. No standardized, clinically validated BPC-157 + TB-500 dosage exists, and understanding why is more useful than any number you could copy.

This guide focuses specifically on the combination, not on either peptide in isolation, and on a detail most sources skip entirely: what is actually sold as "TB-500" is not always the same molecule, which alone makes a universal daily dose impossible to state honestly.

At Dr. Rogers Centers, an integrative internal medicine and gynecology practice in San Antonio, peptide-related questions are handled through individual clinical evaluation rather than a fixed protocol, which is the frame this entire article is built around.

This article is educational and does not provide personalized dosing, injection instructions, or a recommended protocol. Nothing here should be used to self-administer any peptide. Any decision about peptide therapy belongs in a conversation with a licensed clinician.

What Are BPC-157 and TB-500?

BPC-157 is a synthetic pentadecapeptide, a chain of fifteen amino acids, based on a sequence found within a protein present in human gastric juice. Most of what is known about it comes from animal research examining tendon, muscle, bone, and gut injury models, along with a small amount of published human safety data.

"TB-500" is more complicated than it appears. According to the compound’s own technical profile, the name is commonly used for a synthetic heptapeptide, a seven-amino-acid fragment, corresponding to a specific active region of a naturally occurring protein called thymosin beta-4. In practice, however, the name "TB-500" has also been used commercially to refer to full-length synthetic thymosin beta-4 itself, a much larger molecule. Products sold under the same name are not guaranteed to contain the same peptide, at the same concentration, from the same manufacturing process.

That naming inconsistency is not a minor technicality. It means a stated dose is only meaningful if you know exactly which molecule, and which concentration, a given source is actually describing, and most online protocols do not specify this at all.

For background on BPC-157 on its own, including how its evidence base is currently summarized, see our BPC-157 dosage guide, which covers the individual peptide in more depth than this combination-focused article attempts to.

These two peptides are frequently discussed together in recovery and regenerative medicine conversations because both are associated, in preclinical research, with tissue repair and inflammation-related mechanisms. Frequent discussion is not the same as established clinical benefit, and that distinction runs through everything below.

Is There a Standard BPC-157 + TB-500 Dosage?

No. There is no standardized, clinically validated human dosage for BPC-157 combined with TB-500.

A standard combination dose would require more than just individual dosing data for each peptide. It would require studies of the two administered together, examining whether combined exposure changes absorption, effect, or risk compared with either compound alone. That research has not been published. Every "combined dosage" figure circulating online is an assumption stacked on top of two already-uncertain single-agent estimates.

The ranges you find on forums, vendor pages, and social media reflect practitioner-reported anecdotes and online convention, not clinical trial results. They should be read as a description of what some people report doing, not as a validated recommendation for what anyone should do.

BPC-157 + TB-500 Dosage: What the Evidence Actually Shows

For BPC-157, the human evidence is limited but does exist in a small form. A 2025 pilot study examined intravenous infusion in two healthy adults and reported it was well tolerated, though the authors were explicit that a two-person study cannot establish safety at scale. A small 2021 case series looked at intra-articular injection for knee pain without a comparison group. Independent 2025 reviews of the broader literature concluded that human evidence remains inadequate to support clinical dosing recommendations for BPC-157.

For TB-500 specifically, the human evidence gap is wider. Reliable, published human clinical safety and effectiveness data for TB-500, under either the short-fragment or full-length definition, are extremely limited or unavailable in the peer-reviewed literature. Most of what is discussed about TB-500 traces back to veterinary and animal research on thymosin beta-4, plus user-reported experience rather than controlled human study.

No published research has combined the two peptides in a human trial. This means there is no study to cite for a joint dose, a joint duration, or a joint safety profile, regardless of how confidently that combination is described elsewhere.

Evidence and context table

BPC-157 + TB-500 Blend Dosage Per Day

Searches for a blend dosage per day usually assume that a combination product has one settled daily amount. It does not, and the reason is structural rather than a simple gap in the research.

A "blend" can mean an injectable solution mixing two research peptides at whatever ratio a compounder or vendor chooses, an oral capsule formulated at a fixed strength regardless of body size, or a sublingual product with its own absorption profile. Two products both labeled a BPC-157 and TB-500 blend can differ substantially in concentration, ratio, and delivery method, which means a daily figure quoted for one product tells you very little about another.

Dr. Rogers Centers carries Regenatides, an oral capsule combining BPC-157 with a TB-4 fragment, taken once daily. It is a useful real-world illustration of the point above: an oral, fixed-dose capsule is a fundamentally different exposure than a self-mixed injectable solution discussed in an online forum, even when both are described with similar peptide names.

When a specific daily microgram or milligram figure appears online for an injectable blend, it should be read as a reported or anecdotal amount tied to one particular product and one particular person’s experience, not as a medical recommendation transferable to a different product or a different person.

How Much BPC-157 and TB-500 Should You Take?

There is no universally validated human dosing formula for this combination, so this article will not provide one, and any source that gives you a confident "take X mcg of BPC-157 plus X mg of TB-500" figure is presenting an assumption as a fact.

What a qualified clinician would actually consider before discussing any peptide includes the diagnosis and treatment goal, prior treatments already tried, current medications and supplements, relevant personal and family medical history, the specific product’s formulation and verifiable sourcing, the route of administration being considered, and a plan for monitoring and stopping if something does not go as expected. None of that can be replicated by reading a number off a chart.

Does BPC-157 + TB-500 Dosage Depend on Body Weight?

There is no validated human weight-based dosing formula for BPC-157, for TB-500, or for the two combined.

Weight-based dosing is a legitimate concept in medicine, but only once pharmacokinetic studies establish that exposure scales predictably with body mass across a study population, followed by trials confirming the scaled dose behaves as expected. That process has not been carried out for either peptide, and it has certainly not been carried out for the combination. A chart listing a specific dose per kilogram for this pairing is not summarizing a finding; it is presenting an estimate as though it were one.

Body weight is also just one variable among several that would matter to actual absorption and risk, alongside formulation, route, product purity, and individual physiology, none of which a single weight-based number can account for.

What Does a BPC-157 + TB-500 Protocol Actually Mean?

The word "protocol" implies a structured, validated plan. In the context of these two peptides, it more accurately describes a set of choices someone has made, often without clinical supervision, about goal, route, formulation, and duration.

• Treatment goal, since a tendon injury, a muscle strain, and general recovery are treated as separate cases even in the online literature.

• Route of administration, as subcutaneous, intramuscular, or other routes carry very different absorption assumptions.

• Formulation and concentration, since two products with the same name can differ in strength or ratio.

• Duration and any cycling pattern, none of which is grounded in published human outcome data for this combination.

• Monitoring, meaning whether anyone is tracking response or watching for an adverse reaction as the plan proceeds.

• The rest of a recovery plan, including physical therapy, sleep, and nutrition, which often matter more than any injectable substance.

Copying someone else’s protocol carries real risk because it detaches a number from all of this context. You cannot verify their product’s actual contents, their underlying health status, or whether their reported outcome had anything to do with the peptide at all.

Why People Combine BPC-157 and TB-500

The stated rationale usually rests on complementary theoretical mechanisms: BPC-157’s proposed role in local tissue signaling alongside thymosin beta-4’s proposed role in cell migration and wound-related activity, both drawn from separate animal literature. Theoretical complementarity is not proof of combined clinical effectiveness. No published human research demonstrates that combining these two peptides produces better outcomes, faster healing, or added safety compared with either one alone, and describing the pairing as synergistic in a clinical sense goes beyond what the current evidence supports.

Safety Considerations Before Considering a Peptide Protocol

Limited evidence should not be mistaken for demonstrated safety. The few small human studies available for BPC-157 were not designed to detect uncommon or delayed effects, and comparable human safety data for TB-500-specific products is largely absent from the published literature altogether.

Product quality is a separate and serious concern. Material sold as research-use-only is not held to pharmaceutical manufacturing standards, so purity, sterility, and actual peptide content are not verifiable by the person purchasing it. Incorrect storage or reconstitution can further change what is actually being administered, regardless of what the label states.

Injection technique also carries genuine risk, including infection and injection site reactions. Dr. Rogers Centers maintains general patient education on how to prepare an injection for medications prescribed within its own programs, which reflects the level of instruction and oversight appropriate before anyone administers an injectable substance to themselves.

Individual health factors deserve a direct conversation with a physician rather than an assumption either way, including any personal or family history of cancer, given that tissue growth and blood vessel formation are among the proposed mechanisms for both peptides, as well as pregnancy, autoimmune conditions, and current medications.

Where a Clinical Conversation Fits

If a persistent injury or recovery concern is what brought you here, a structured evaluation of what is actually causing the problem is usually more productive than researching an unregulated peptide combination further.

For musculoskeletal complaints specifically, Dr. Rogers Centers’ multispecialty joint care program reflects a stepwise approach: diagnosis first, then a discussion of which supported treatments, if any, fit the actual problem, before an experimental compound would even be relevant.

That kind of evaluation also surfaces options with more established evidence behind them, whether that is a specific therapy for the diagnosed condition or addressing an underlying factor like nutrition, training load, or sleep that is quietly limiting recovery regardless of what peptide is added on top of it. In many cases, a patient’s recovery stalls not because the wrong peptide was chosen, but because one of these ordinary contributing factors was never properly assessed in the first place, and no combination of experimental compounds can substitute for identifying it.

Recovery and longevity-focused care at the practice, including where peptide-related questions are discussed, sits within its broader longevity and advanced recovery services, where decisions are made individually rather than from a fixed online protocol.

Key Takeaways

• There is no standardized, clinically validated BPC-157 + TB-500 dosage, and no published human trial has studied the combination.

• "TB-500" is used inconsistently in the market to describe different molecules, which alone makes a universal dose impossible to state honestly.

• Human evidence for BPC-157 alone is limited to small pilot and case-series data. Human data specific to TB-500 products is essentially absent from the published literature.

• A "blend dosage per day" depends entirely on the specific product’s formulation, concentration, and route, which vary widely between sources.

• No validated weight-based dosing formula exists for either peptide or for the combination.

• Theoretical complementary mechanisms do not establish that combining the two peptides is more effective or safer than using either alone.

• Product purity, sourcing, and injection technique are genuine safety concerns with unregulated material.

• Any specific plan belongs in a conversation with a licensed clinician who can evaluate your diagnosis, history, and goals directly.

To discuss a recovery concern with a physician-led team rather than an online protocol, you can contact Dr. Rogers Centers directly.

Frequently Asked Questions

What is the usual BPC-157 and TB-500 dosage?

There is no usual or standard dosage established by human research for this combination. Figures found online come from anecdotal reports and vary by product, route, and source, not from clinical trials.

How much BPC-157 and TB-500 should you take?

This has not been established in human research, so no specific amount can be responsibly recommended here. A qualified clinician would evaluate your diagnosis, history, and goals before discussing any peptide, rather than starting from a fixed number.

Can BPC-157 and TB-500 be taken together?

People do report combining them, based on theoretical complementary mechanisms observed separately in animal research. No published human trial has tested the combination, so its effectiveness and safety together are not established.

Is there a BPC-157 + TB-500 dosage per day?

No validated daily dosage exists for the combination. Reported daily amounts online are tied to specific unregulated products and are not transferable to a different product or person.

Is there a reliable BPC-157 + TB-500 dosage chart?

No. A responsible chart can show what categories of evidence exist and where they stop, which is what the table in this article does, but it cannot responsibly assign specific doses without human trial data to support them.

Does BPC-157 + TB-500 dosage depend on body weight?

There is no validated weight-based formula for either peptide individually or for the combination. Weight-based charts circulating online are estimates, not findings from human dosing studies.

How long is a BPC-157 + TB-500 protocol?

Cycle lengths discussed online vary widely and are not based on published human outcome data for this combination. No duration has been validated in cocontrolled researchArArePC-157 and TB-500 safe?

Safety has not been established in humans for either peptide individually, and even less so for the combination. Concerns include limited safety data, unregulated product quality, and injection-related risks. Individual risk should be discussed with a qualified healthcare professional.